426 related articles for article (PubMed ID: 38334807)
21. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies.
Kessler T; Fehrmann F; Bieker R; Berdel WE; Mesters RM
Curr Drug Targets; 2007 Feb; 8(2):257-68. PubMed ID: 17305503
[TBL] [Abstract][Full Text] [Related]
23. Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
Al Hadidi S; Schinke C; Thanendrarajan S; Zangari M; van Rhee F
JAMA Netw Open; 2022 Apr; 5(4):e228161. PubMed ID: 35442451
[TBL] [Abstract][Full Text] [Related]
24. The Role of RNA-Binding Proteins in Hematological Malignancies.
Aguilar-Garrido P; Otero-Sobrino Á; Navarro-Aguadero MÁ; Velasco-Estévez M; Gallardo M
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076951
[TBL] [Abstract][Full Text] [Related]
25. p21-Activated kinases as promising therapeutic targets in hematological malignancies.
Wu A; Jiang X
Leukemia; 2022 Feb; 36(2):315-326. PubMed ID: 34697424
[TBL] [Abstract][Full Text] [Related]
26. Treating hematological malignancies with cell therapy: where are we now?
Landoni E; Savoldo B
Expert Opin Biol Ther; 2018 Jan; 18(1):65-75. PubMed ID: 28978241
[TBL] [Abstract][Full Text] [Related]
27. Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
Lin HC; Yang YS; Teng CJ; Shen CH; Jan YG; Cheng SB; Wu CC; Lin YL; Huang CC; P'eng FK
World J Surg Oncol; 2017 Nov; 15(1):194. PubMed ID: 29096656
[TBL] [Abstract][Full Text] [Related]
28. B-cell maturation antigen expression across hematologic cancers: a systematic literature review.
Dogan A; Siegel D; Tran N; Fu A; Fowler J; Belani R; Landgren O
Blood Cancer J; 2020 Jun; 10(6):73. PubMed ID: 32606424
[TBL] [Abstract][Full Text] [Related]
29. [Angiogenesis and hematological malignancies].
Iversen PO
Tidsskr Nor Laegeforen; 2003 Nov; 123(22):3198-200. PubMed ID: 14714007
[TBL] [Abstract][Full Text] [Related]
30. Reprogramming cell death: BCL2 family inhibition in hematological malignancies.
Scarfò L; Ghia P
Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849
[TBL] [Abstract][Full Text] [Related]
31. Checkpoint inhibition in pediatric hematologic malignancies.
Davis KL; Agarwal AM; Verma AR
Pediatr Hematol Oncol; 2017; 34(6-7):379-394. PubMed ID: 29190182
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma.
Vasudevan Nampoothiri R; Pasic I; Law AD; Lam W; Chen C; Michelis FV; Kim DDH; Gerbitz A; Lipton JH; Kumar R; Mattsson J; Viswabandya A
Eur J Haematol; 2022 May; 108(5):430-436. PubMed ID: 35100661
[TBL] [Abstract][Full Text] [Related]
33. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Khan AN; Asija S; Pendhari J; Purwar R
Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
[TBL] [Abstract][Full Text] [Related]
34. Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer.
Jeong Y; Xie Y; Xiao G; Behrens C; Girard L; Wistuba II; Minna JD; Mangelsdorf DJ
PLoS Med; 2010 Dec; 7(12):e1000378. PubMed ID: 21179495
[TBL] [Abstract][Full Text] [Related]
35. Emerging role of exosomes in hematological malignancies.
Pandian SRK; Vijayakumar KK; Kunjiappan S; Babkiewicz E; Maszczyk P
Clin Exp Med; 2023 Aug; 23(4):1123-1136. PubMed ID: 35798882
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic potentials of melatonin in the treatment of lymphoma: A review of current evidence.
Moradian F; Pourhanifeh MH; Mehrzadi S; Karimi-Behnagh A; Hosseinzadeh A
Fundam Clin Pharmacol; 2022 Oct; 36(5):777-789. PubMed ID: 35384044
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological and therapeutic potentials of cordycepin in hematological malignancies.
Taghinejad Z; Kazemi T; Fadaee M; Farshdousti Hagh M; Solali S
Biochem Biophys Res Commun; 2023 Oct; 678():135-143. PubMed ID: 37634411
[TBL] [Abstract][Full Text] [Related]
38. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
39. Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies.
Li L; Chai Y; Wu C; Zhao L
Expert Rev Hematol; 2020 Dec; 13(12):1387-1396. PubMed ID: 33170753
[TBL] [Abstract][Full Text] [Related]
40. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
